Advanced

Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.

Nikitidou, Litsa LU ; Torp, Malene; Fjord-Larsen, Lone; Kusk, Philip; Wahlberg, Lars U and Kokaia, Merab LU (2014) In Epilepsia 55(1). p.167-174
Abstract
Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to... (More)
Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to rapid kindling, a model for recurrent temporal lobe seizures. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Epilepsia
volume
55
issue
1
pages
167 - 174
publisher
Wiley-Blackwell
external identifiers
  • wos:000329893900021
  • pmid:24245512
  • scopus:84892907722
ISSN
0013-9580
DOI
10.1111/epi.12470
language
English
LU publication?
yes
id
0eed1f37-f991-4b72-9cef-3d2ad1cb7353 (old id 4179212)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24245512?dopt=Abstract
date added to LUP
2013-12-03 17:54:02
date last changed
2017-01-01 04:01:15
@article{0eed1f37-f991-4b72-9cef-3d2ad1cb7353,
  abstract     = {Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to rapid kindling, a model for recurrent temporal lobe seizures.},
  author       = {Nikitidou, Litsa and Torp, Malene and Fjord-Larsen, Lone and Kusk, Philip and Wahlberg, Lars U and Kokaia, Merab},
  issn         = {0013-9580},
  language     = {eng},
  number       = {1},
  pages        = {167--174},
  publisher    = {Wiley-Blackwell},
  series       = {Epilepsia},
  title        = {Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.},
  url          = {http://dx.doi.org/10.1111/epi.12470},
  volume       = {55},
  year         = {2014},
}